News

Virginia Governor Glenn Youngkin named BIO’s Governor of the Year

Today, the Biotechnology Innovation Organization (BIO) awarded Virginia Governor Glenn Youngkin with its 2024 Governor of the Year Award.

BIO’s annual award honors governors for their leadership and commitment to strengthening biotechnology in their state. For over a decade, the award has recognized governors from across the country and both sides of the aisle.

“Investing in biotechnology is investing in Virginia’s future,” said Governor Glenn Youngkin. “As the Commonwealth’s cutting-edge research triangle and network continues to expand, my administration is determined to remain at the forefront of fostering innovation. I am incredibly humbled to receive this award, and I look forward to further solidifying Virginia’s role as a leader in the life sciences industry.”

“It is my honor to recognize Governor Youngkin with BIO’s 2024 Governor of the Year award for his leadership and support of the life sciences in Virginia,” said BIO President and CEO John F. Crowley. “From advancing innovative economic development initiatives for the bioscience ecosystem to investing in cutting-edge life science facilities across the state, Governor Youngkin has worked tirelessly on public policy solutions to help expand opportunities for researchers, entrepreneurs, and patients in Virginia.”

“Virginia’s $8 billion biotechnology industry is thriving because of the steadfast support of our governmental leaders and regional partnerships,” said John Newby, CEO of the Virginia Biotechnology Association. “We thank Governor Youngkin and his administration for making transformational investments in our ecosystem, and for promoting pro-innovation policies that bring life-improving technologies to patients.”

Read more here.

Recent News

04/24/2026

Skyphos Technologies Has Been Awarded its Second U.S. Patent

Skyphos Technologies has been awarded its second U.S. patent, adding to a growing intellectual property portfolio that now includes nearly a dozen patent applications in process around the world. This latest patent secures core technologies and methods that allow micro-scale parts to be produced in seconds, at throughputs designed to exceed legacy manufacturing such as

04/23/2026

CollectiveMinds LLC Places Keith Meadors as Chief Commercial Officer at Genova Diagnostics

CollectiveMinds LLC, a leading executive search firm specializing in life sciences and healthcare, today announced the successful placement of Keith Meadors as Chief Commercial Officer of Genova Diagnostics, a pioneer in advanced diagnostic testing. The appointment marks another milestone for CollectiveMinds in connecting exceptional leadership talent with high-growth organizations across the diagnostics and life sciences

04/22/2026

RIVANNA expands multi-site clinical study for Accuro XV musculoskeletal imaging system

RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies evaluating Accuro® XV, the company’s musculoskeletal imaging system, from two to eight sites nationwide. This expansion follows execution of a funding option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response